EMA has recommended extending the indication of Ofev (nintedanib) to include the treatment of progressive fibrosing interstitial lung diseases (ILDs) in children and adolescents from the age of 6. Currently there are no approved therapies for these conditions in children.
Fibrosing ILDs encompass a group of complex and heterogeneous rare respiratory disorders that can be linked to many causes, including autoimmune conditions like systemic sclerosis. Fibrosing ILDs are characterised by the build-up of scarring in the lungs, which leads to breathing difficulties. Ofev is already authorised in the European Union for the treatment of fibrosing ILDs in adults.
The active substance in Ofev, nintedanib, blocks the activity of some enzymes known as tyrosine kinases. These enzymes are involved in the generation of scar tissue. By blocking these enzymes, nintedanib helps to reduce the formation of scarring in the lungs, preventing the symptoms of the disease from getting worse…
